申请人:Van Gestel Frans Elisabetha Jozef
公开号:US20050148581A1
公开(公告)日:2005-07-07
The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib)
the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as
Mycobacterium tuberculosis, M. bovis, M. avium
and
M. marinum
. In particular, compounds are claimed in which, independently from each other, R
1
is bromo, p=1, R
2
is alkyloxy, R
3
is optionally substituted naphthyl or phenyl, q=1, R
4
and R
5
each independently are hydrogen, methyl or ethyl, R
6
is hydrogen, r is equal to 0 or 1 and R
7
is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
本发明涉及符合通式(Ia)或通式(Ib)的新型取代喹啉衍生物
其药学上可接受的酸或碱加成盐、其立体化学异构体形式、其同分异构体形式和其 N-氧化物形式。所要求的化合物可用于治疗分枝杆菌疾病,特别是由致病分枝杆菌引起的疾病,如
结核分枝杆菌、牛分枝杆菌、禽分枝杆菌
和
M. marinum
.具体而言,本发明要求的化合物中,R
1
是溴,p=1,R
2
是烷氧基,R
3
是任选取代的萘基或苯基,q=1,R
4
和 R
5
各自独立地为氢、甲基或乙基,R
6
是氢,r 等于 0 或 1,R
7
是氢。本发明还要求一种组合物,该组合物包含药学上可接受的载体和作为活性成分的治疗有效量的所称化合物,使用所称化合物或组合物制造治疗霉菌病的药物,以及制备所称化合物的工艺。